

Anti-VEGF [Bevacizumab] Standard Size Ab00715-10.0

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Isotype and Format: Human IgG1, Kappa

Clone Number: Bevacizumab

Alternative Name(s) of Target: asclar Endothelial Growth Factor; VEGF-A; VEGFA; Vascular Permeability Factor; VPF

UniProt Accession Number of Target Protein: P15692

Published Application(s): IP, WB, Block, ELISA, FC

Published Species Reactivity: Human

Immunogen: Recombinant human VEGF.

Specificity: This antibody binds native and reduced human VEGF (isoform 165).

Application Notes: This is a research-grade biosimilar against VEGF. VEGF is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels.

Antibody First Published in: Kim et al. The Vascular Endothelial Growth Factor Proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7(1):53-64.

[PMID:1380254](#)

Note on publication: Describes generation of anti-hVEGF monoclonal antibodies as well as characterisation of binding by various methods. Also shows inhibition of angiogenesis and vascular permeabilization induced by human VEGF in a model organisms.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.